Why Is 10X GENOMICS INC A (TXG) Stock Down Today?

10x Genomics (TXG) shares declined 5.48% to $71.93 on Wednesday. The primary driver of the move was a multi-project research collaboration announced with Fred Hutchinson Cancer Center, which extends the company’s oncology push into blood cancers and solid tumors.

What Happened

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center aimed at advancing single cell and spatial applications across solid tumors and blood cancers. The effort is described as the company’s first clinical research initiative in this specific area, focusing on biomarker discovery in advanced bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia.

Despite the strategic partnership, the stock faced downward pressure. Barclays raised its price target on the shares to $110 from $52 while maintaining an Overweight rating. Leerink Partners also maintained a Market Perform rating and raised its price target to $90. However, the positive analyst actions did not offset the broader market reaction to the news.

What The Data Shows

The stock opened at $73.84, representing a 3.0% gap down from the prior close of $76.10. The session high reached $74.18 at 9:30 AM ET, while the session low hit $71.01 at 9:35 AM ET. Volume so far stands at 0.4 million shares, which is 0.1 times the 3-month daily average.

Fundamentals indicate a market cap of $10.5 billion. The company remains unprofitable with a trailing twelve-month EPS of -$0.59 and revenue down 4.3% over the same period. The net margin is -12.2%, and the stock carries a beta of 1.99. The 52-week range is $11.16 to $102.81. Over the last eight sessions, the stock has moved down 14.0% from $88.50 to $76.10. Recent insider activity shows 11 sells totaling $12.2 million in the last 90 days, with no buys recorded. The most recent filings were from CEO Serge Saxonov and Director Suliman Shehnaaz on September 22, 2026.

What To Watch

Investors will monitor how the market digests the Fred Hutchinson collaboration alongside the recent price target increases from major banks. The lack of recent insider buying and the high beta suggest continued volatility as the stock navigates its current valuation.